- Home
- RBNE vs APLM Comparison
RBNE vs APLM Comparison
Compare RBNE & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBNE
- APLM
- Stock Information
- Founded
- RBNE 2024
- APLM 2016
- Country
- RBNE Cyprus
- APLM United States
- Employees
- RBNE N/A
- APLM N/A
- Industry
- RBNE Marine Transportation
- APLM Blank Checks
- Sector
- RBNE Consumer Discretionary
- APLM Finance
- Exchange
- RBNE Nasdaq
- APLM Nasdaq
- Market Cap
- RBNE 7.3M
- APLM 6.1M
- IPO Year
- RBNE N/A
- APLM N/A
- Fundamental
- Price
- RBNE $1.30
- APLM $18.43
- Analyst Decision
- RBNE
- APLM
- Analyst Count
- RBNE 0
- APLM 0
- Target Price
- RBNE N/A
- APLM N/A
- AVG Volume (30 Days)
- RBNE 4.3M
- APLM 88.1K
- Earning Date
- RBNE 09-30-2025
- APLM 09-30-2025
- Dividend Yield
- RBNE N/A
- APLM N/A
- EPS Growth
- RBNE N/A
- APLM N/A
- EPS
- RBNE N/A
- APLM N/A
- Revenue
- RBNE N/A
- APLM $198,000.00
- Revenue This Year
- RBNE N/A
- APLM $415.15
- Revenue Next Year
- RBNE N/A
- APLM N/A
- P/E Ratio
- RBNE N/A
- APLM N/A
- Revenue Growth
- RBNE N/A
- APLM N/A
- 52 Week Low
- RBNE $1.23
- APLM $3.66
- 52 Week High
- RBNE $20.57
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- RBNE N/A
- APLM 90.29
- Support Level
- RBNE N/A
- APLM $3.66
- Resistance Level
- RBNE N/A
- APLM $6.37
- Average True Range (ATR)
- RBNE 0.00
- APLM 1.62
- MACD
- RBNE 0.00
- APLM 1.20
- Stochastic Oscillator
- RBNE 0.00
- APLM 85.30
About RBNE Robin Energy Ltd. Common Stock
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.